<DOC>
	<DOCNO>NCT00577863</DOCNO>
	<brief_summary>This study conduct collect information subject osteoporosis regard experience use Forteo B Pen self-administer teriparatide community set . Information collect study use assess need change Forteo B-Pen User Manual patient educational tool . Additionally , information generate patient trial review assess acceptability Forteo B Pen commercial launch .</brief_summary>
	<brief_title>Study Experience Patients With Osteoporosis Using Forteo B Pen Self Administer Once Daily Teriparatide Therapy</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>1 . Men primary hypogonadal osteoporosis postmenopausal woman osteoporosis opinion investigator . Subjects must high risk fracture opinion investigator . 2 . Willing trained use peninjector daily satisfaction study site personnel . 3 . Able read , understand , respond selfadministered questionnaire . 4 . Without language barrier , cooperative , expect return followup procedure . 5 . Have provide write informed consent participate study , accord local regulation inform risk , medication , procedure use study . 6 . Any disease sufficient severity preclude treatment teriparatide participation completion study define investigator . 7 . Having laboratory value , elevate serum calcium , preclude teriparatide treatment define investigator . 8 . Subjects increase baseline risk osteosarcoma , include : Paget 's disease bone unexplained elevation alkaline phosphatase , child young adult open epiphysis , subject receive external beam implant radiation therapy involve skeleton . 9 . History malignant neoplasms 5 year prior study entry , exception superficial basal cell carcinoma squamous cell carcinoma skin definitively treat , history carcinoma situ cervix uterus .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>